Spyre Therapeutics Inc Quick Ratio (SYRE) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Spyre Therapeutics Inc   (NASDAQ: SYRE)

Spyre Therapeutics Inc 's Quick Ratio

SYRE's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Spyre Therapeutics Inc 's Cash & cash equivalent grew by 48.35 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Spyre Therapeutics Inc 's Quick Ratio to 28.48 a new company high.

Within Major Pharmaceutical Preparations industry 16 other companies have achieved higher Quick Ratio than Spyre Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 122, from total ranking in the first quarter 2026 at 210.

Explain Quick Ratio?
How much Cash & cash equivalents SYRE´s has?
What are SYRE´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SYRE Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change -53.5 % 20.49 % -35.28 % -19.58 % 275.46 %
Y / Y Cash & cash equivalent Change 108.9 % 31.27 % 98.55 % 17.37 % 23.61 %
Quick Ratio MRQ 28.48 8.71 20.4 10.51 6.34
SYRE's Total Ranking # 122 # 210 # 121 # 257 # 217
Seq. Current Liabilities Change -54.65 % 45.12 % 26.82 % -44.29 % 17.52 %
Seq. Cash & cash equivalent Change 48.35 % -38.08 % 146.28 % -7.67 % -6.77 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 17
Healthcare Sector # 28
Overall Market # 122


Quick Ratio Statistics
High Average Low
28.48 9.22 1.01
(Jun 30 2026)   (Jun 30 2023)




Financial Statements
Spyre Therapeutics Inc 's Current Liabilities $ 39 Millions Visit SYRE's Balance sheet
Spyre Therapeutics Inc 's Cash & cash equivalent $ 1,100 Millions Visit SYRE's Balance sheet
Source of SYRE's Sales Visit SYRE's Sales by Geography


Cumulative Spyre Therapeutics Inc 's Quick Ratio

SYRE's Quick Ratio for the trailling 12 Months

SYRE Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -24.25 % 13.34 % 21.36 % 109.48 % 139.45 %
Y / Y Cash & cash equivalent TTM Growth 67.17 % 46.99 % 43.94 % 31.04 % 45.08 %
Quick Ratio TTM 15.41 10.8 10.73 7.5 6.98
Total Ranking TTM # 3243 # 1793 # 1749 # 2516 # 2631
Seq. Current Liabilities TTM Growth -16.27 % 5.6 % -11.01 % -3.73 % 25.28 %
Seq. Cash & cash equivalent TTM Growth 19.43 % 6.37 % 27.25 % 3.41 % 5.01 %

Quick ratio ranking by company, industry and sector >> Back to SYRE Financial Strength Comparisons >> Go to Compare SYRE Quick Ratio to its Competitors

On the trailing twelve months basis SYRE Cash & cash equivalent more than doubled by 108.9 % in Q2 2026 year on year, while Current Liabilities dropped to $39 millions, this led to increase in in Spyre Therapeutics Inc 's Quick Ratio to 15.41, above SYRE average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 411 other companies have achieved higher Quick Ratio than Spyre Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 1793 to 3243.

Explain Quick Ratio?
How much Cash & cash equivalents SYRE´s has?
What are SYRE´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 412
Healthcare Sector # 833
Within the Market # 3243


trailing twelve months Quick Ratio Statistics
High Average Low
17.39 8.08 1.45
(Mar 31 2017)   (Jun 30 2023)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Contineum Therapeutics Inc   70.25 $ 458.440  Millions$ 6.526  Millions
Sagimet Biosciences inc   61.23 $ 331.832  Millions$ 5.419  Millions
Avalyn Pharma Inc   49.93 $ 539.733  Millions$ 10.809  Millions
Pasithea Therapeutics Corp   49.76 $ 91.464  Millions$ 1.838  Millions
Disc Medicine Inc   44.03 $ 1,336.770  Millions$ 30.360  Millions
Trevi Therapeutics Inc   36.50 $ 318.870  Millions$ 8.736  Millions
Design Therapeutics Inc   35.76 $ 401.889  Millions$ 11.240  Millions
Mineralys Therapeutics Inc   34.87 $ 673.704  Millions$ 19.319  Millions
Praxis Precision Medicines Inc   34.32 $ 1,683.790  Millions$ 49.058  Millions
Agios Pharmaceuticals Inc   33.94 $ 2,383.112  Millions$ 70.217  Millions
Mbx Biosciences Inc   33.10 $ 783.099  Millions$ 23.660  Millions
Xbiotech Inc   32.67 $ 109.528  Millions$ 3.353  Millions
Avalo Therapeutics Inc   31.89 $ 787.143  Millions$ 24.682  Millions
Fulcrum Therapeutics Inc   30.96 $ 318.840  Millions$ 10.298  Millions
Climb Bio Inc   30.86 $ 183.123  Millions$ 5.934  Millions
Indaptus Therapeutics Inc   29.61 $ 15.554  Millions$ 0.525  Millions
Crinetics Pharmaceuticals Inc   29.41 $ 2,350.275  Millions$ 79.915  Millions
Spyre Therapeutics Inc   28.48 $ 1,100.000  Millions$ 38.620  Millions
Curanex Pharmaceuticals Inc  28.17 $ 2.938  Millions$ 0.104  Millions
Onkure Therapeutics Inc   28.04 $ 186.284  Millions$ 6.643  Millions
Ligand Pharmaceuticals Incorporated  27.33 $ 1,277.438  Millions$ 46.736  Millions
Shattuck Labs Inc   26.94 $ 208.300  Millions$ 7.731  Millions
Cryoport inc   26.87 $ 785.860  Millions$ 29.244  Millions
Roivant Sciences Ltd   26.82 $ 7,607.076  Millions$ 283.603  Millions
Palvella Therapeutics Inc   26.23 $ 313.381  Millions$ 11.947  Millions
Upstream Bio Inc   26.16 $ 261.307  Millions$ 9.988  Millions
Rallybio Corporation  26.02 $ 92.800  Millions$ 3.567  Millions
Assembly Biosciences Inc   25.95 $ 608.475  Millions$ 23.445  Millions
Arbutus Biopharma Corp  25.84 $ 92.625  Millions$ 3.585  Millions
Immix Biopharma Inc   25.49 $ 238.715  Millions$ 9.364  Millions

Date modified: 2026-09-02T17:47:53+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.